In this environment, the use of anti-CD38 mAbs depletes CD38+ MDSCs, T regs, and B regs immune suppressive cells and enhances antitumor activity [52, 53], but as anti-CD38 mAbs downregulates CD38 expression in tumor cells, immune escape, and disease progression is favored [54]. Here, CD38 is linked to neoplasm.